癌相关糖抗原125在女性生殖系统肿瘤诊断中的应用

Application of CA125 in Diagnosing Genital Tumors in Female

目的 探讨癌相关糖抗原 12 5 (CA12 5 )在女性生殖系统肿瘤诊断的应用价值。方法 应用酶联免疫吸附(EL ISA)试验定量测定了 5 5 8例妇科住院患者和 92例健康妇女血清中 CA12 5的含量。结果 卵巢恶性肿瘤组、非卵巢妇科恶性肿瘤组、卵巢良性肿瘤组、子宫良性肿瘤组以及妇科良性疾病组 CA12 5分别为 45 4.0 U/ ml± 5 0 7.4U/ ml,15 9.3U / ml± 336 .9U/ ml,5 2 .9U / ml± 139.2 U / ml和 36 .9U/ ml± 75 .7U / ml,与健康对照组比较 ,除妇科良性疾病组无显著差异外 (P>0 .0 5 ) ,其余各组差异均有显著意义 (P<0 .0 5 ) ;卵巢恶性肿瘤组与各组比较有极显著差异 (P<0 .0 1)。CA12 5在诊断卵巢恶性肿瘤的阳性检出率远高于其余各组 ,敏感性、特异性和有效性分别为 87.5 %、79.3%、77.7%。结论 CA12 5动态测定对卵巢癌的早期诊断。

Objective To investigate the application of CA125 in diagnosing genital tumors in females.Methods 588 patients and 92 healthy females were collected and sera concentration of CA125 was examined quantitatively by the method of enzyme linked immunosorbent assay(ELISA).Results Sera concentration of CA125 was 454.0U/ml± 507.4 U/ml,159.3U/ml±336.9U/ml,52.9U/ml±139.2U/ml,36.9U/ml±75.7U/ml in ovarian cancer group,non ovarian cancer group,benign ovarian tumor group, benign womb tumor group and other benign diseases group respectively.Except for the benign diseases group,the CA125 levels of the other 3 groups showed significance when compared with control(P<0.05),and the malignant tumor group showed remarkale significance(P<0.01).The sensitivity,specificity and validity of diagnosing malignant ovarian cancer by examining CA125 were 87.5%,79.3%,77.7%,respectively.Conclusion Monitoring CA125 dynamically might be of certain significance for diagnosing ovarian cancer in early stage,observing the curative effect and predicting the recurrence.